Company Overview and News
KUALA LUMPUR (Aug 8): The FBM KLCI pared some of its gains at mid-morning today, struggling to breach the 1,800-point level.
PBLOF BATS 4162 7087 7043 1295 5168 5014 5007 KLKBY 5029 2445 2542 5225 3867 5517 7668 2739 MYPRY 2836 Q0F IHHHF HRGHY
KUALA LUMPUR (Aug 3): The FBM KLCI retreated at mid-morning today, dragged by losses at Telekom Malaysia Bhd (TM) and other select blue chips, against the backdrop of a set of tentative regional markets.
HLFBF UPBMF 1082 7113 5681 TPGVF 5015 2089 0020 TGLVY 4863 3867 0126 5517 5819 MYTEF 2836
KUALA LUMPUR (July 30): The appointment of the new board of directors for Khazanah Nasional Bhd, which include experts from the corporate world, will provide a clear business and operational direction for the sovereign wealth fund going forward, thus elevating it to greater heights.
KUALA LUMPUR, July 30 — The appointment of new Khazanah Nasional Bhd’s board of directors, which includes experts from the corporate world, will provide a clear business and operational direction for the sovereign wealth fund going forward, thus elevating it to greater heights.
KUALA LUMPUR: Malaysian Prime Minister Mahathir Mohamad has been appointed chairman of the board of Khazanah Nasional Berhad, with immediate effect, the Prime Minister's Office announced on Monday (Jul 30) in a statement.
Kiddie Summer Camp CHILDREN CAN immerse themselves in fun-filled summer workshops — ranging from coloring activities to performing arts, and kiddie combat — at Lucky Chinatown’s Kiddie Summer Camp until May 20. Each activity will be facilitated by a group that will help kids nurture interest in their chosen category. Sessions will be available both in the morning and afternoon. On April 20 and 21, kids can advance their coloring skills during the Crayola Arts Classes with the Masters of Likhang Bata Creativity Center at 2 p.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...